Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Cubist Pharmaceuticals (Nasdaq: CBST) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Cubist's business and see what CAPS investors are saying about the stock right now.

Cubist facts

Headquarters (founded) Lexington, Mass. (1992)
Market Cap $2.4 billion
Industry Biotechnology
Trailing-12-Month Revenue $803.1 million
Management CEO Michael Bonney
CFO David McGirr
Return on Equity (average, past 3 years) 14.1%
Cash/Debt $790.2 million / $462.1 million
Competitors Astellas Pharma
Pfizer
Teva Pharmaceutical

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 95% of the 324 members who have rated Cubist believe the stock will outperform the S&P 500 going forward.  

Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bull case for our community:

I like to green thumb Cubist on pullbacks, since their consistently strong Cubicin revenues provide substantial downside protection. The company also has a strong internal pipeline which has the potential to generate substantial positive catalysts in the near future. I wasn't impressed with the Adolor acquisition, but under new management Entereg is actually showing some signs of life.

If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Cubist may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.